Maxim Group initiates coverage on CASI Pharmaceuticals (NASDAQ: CASI) with a Buy rating and a price target of $4.00.Analyst Gabrielle ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE